

Curriculum Vitae
PAUL O. GUBBINS, PHARM.D. FCCP
March, 2010

	Telephone:	(501) 225-4469
	Date of Birth:	8/29/64
Work:	University of Arkansas for Medical Sciences Department of Pharmacy Practice, College of Pharmacy 4301 West Markham, #522-4 Little Rock, AR 72205-7122	Work: (501)686-6683 e-mail: <i>gubbinspaulo@uams.edu</i> FAX: (501) 686-8315 SSN: Available on request Licensure: Kentucky Arkansas

CURRENT POSITION:

Chair, Department of Pharmacy Practice, University of Arkansas for Medical Sciences, College of Pharmacy. Appointed May, 2004-present.

Professor Pharmacy Practice, University of Arkansas for Medical Sciences, College of Pharmacy. Appointed July 01, 2005- present.

Graduate Faculty, University of Arkansas for Medical Sciences, Graduate School, Appointed November 18, 2004- present.

Associate Professor, Department of Health Policy & Management, University of Arkansas for Medical Sciences, College of Public Health. Appointed January 14, 2005-present.

FELLOWSHIP TRAINING:

Infectious Disease/ Critical Care, University of Illinois at Chicago College of Pharmacy Chicago, Illinois. Infectious Disease Fellow Pharmacy Practice, July 1, 1990 to June 1992.

RESIDENCY TRAINING:

University of Kentucky, Albert B. Chandler Medical Center, Lexington, Kentucky. Resident in Clinical Pharmacy, July 1, 1988 to June 1990.

EDUCATION EXPERIENCE:

Pre-Pharmacy: University of Illinois Urbana/Champaign, College of Liberal Arts and Science. September 1982 - May 1984.

Pharmacy: University of Illinois at Chicago College of Pharmacy. September 1984 - June 1988 Degree: Pharm.D.

PROFESSIONAL EXPERIENCE:

July 1988 to July 1990 Albert B. Chandler Medical Center Hospital Pharmacy University of Kentucky, Lexington, Kentucky, Pharm.D. Resident/Staff Pharmacist.

ACADEMIC APPOINTMENTS:

July 1998 to June 2005 Associate Professor Pharmacy Practice, University of Arkansas for Medical Sciences, College of Pharmacy.

July 1996 to August 2005 Director, Infectious Disease Pharmacology Fellowship, Department of Pharmacy Practice University of Arkansas for Medical Sciences, College of Pharmacy.

May 2003 to May 2004 Acting Chair, Department of Pharmacy Practice, University of Arkansas for Medical Sciences, College of Pharmacy.

July 1992 to June 1998 Assistant Professor, Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, AR.

July 1990 to July 1992 Clinical Assistant Instructor, University of Illinois at Chicago, Chicago, IL.

TEACHING ACTIVITIES:

Fellows Trained

2003-05 Jarrett R. Amsden, Pharm.D. *current position:* Assistant Professor, Pharmacy Practice, College of Pharmacy, Butler University, Indianapolis, IN

1998-00 Scott McConnell, Pharm.D. *current position:* Clinical Scientific Director Cubist Pharmaceuticals; Clinical Assistant Professor, Pharmacy Practice, College of Pharmacy, Creighton University, Omaha, NE

1996-98 Scott R. Penzak, Pharm.D. *current position:* Clinical Pharmacokinetics Lab, Department of Pharmacy, NIH Clinical Center, Bethesda, MD.

Resident Preceptor

Infectious Disease consult service, College of Pharmacy, University Hospital, University of Arkansas for Medical Sciences August 1992 –present.

Infectious Disease consult service, University of Illinois at Chicago, College of Pharmacy, University Hospital, & Humana Michael Reese Hospital, University of Illinois at Chicago, July 1990-June 1992.

Instructor

Experiential

Pharmacy Student Preceptor Adult Internal Medicine/ Infectious Disease Consult Service, University Hospital, University of Arkansas for Medical Sciences College of Pharmacy, 1993-2004.

Pharmacy Student Preceptor; Infectious Disease Consult Service, Humana Michael Reese Hospital, University of Illinois at Chicago College of Pharmacy, 1990-92.

Didactic

Pharmacy Management (PhPr) College of Pharmacy, University of Arkansas for Medical Sciences, 2010-present Course co-coordinator, and lecturer.

Political Advocacy in Pharmacy (PHPR 5282) College of Pharmacy, University of Arkansas for Medical Sciences, 2004-2006 Course co-developer, coordinator, and lecturer.

TEACHING ACTIVITIES: *Didactic (continued)*

Advanced Infectious Disease Therapeutics (PHPR 5352). College of Pharmacy, University of Arkansas for Medical Sciences, Course developer, coordinator, and lecturer. 1996-2005.

Therapeutics II (PHPR 5626), Infectious Diseases, College of Pharmacy, University of Arkansas for Medical Sciences, Instructor 1993-present Course-coordinator 2009-present.

NUSC 5043, Clinical Pharmacology and Therapeutics in Advanced Nursing Practice, Graduate School, University of Arkansas for Medical Sciences 1996, lecturer.

Pharmacy Practice (PHR 831, 868, 870) College of Pharmacy, University of Kentucky 1988-90, lecturer.

COMMITTEES & APPOINTMENTS:

University (selected)

University of Arkansas for Medical Sciences Committee on Clinical Research. Member 2009-present

University of Arkansas for Medical Sciences Non-Academic Staff Conflict of Interest Committee. Chair, 2008-present

University of Arkansas for Medical Sciences Faculty Conflict of Interest Committee. Member 2006-present

University of Arkansas for Medical Sciences Institute on Aging Chairman Search Committee member, 2008-2009

University of Arkansas for Medical Sciences ICTSA Regulatory Support Subcommittee. Member 2006-2007.

University of Arkansas for Medical Sciences Criteria 5 Committee for North Central Association (NCA) Accreditation Project. Member 2005-2007

University of Arkansas for Medical Sciences Medical Research Endowment Review Board. Member 2004-present

Federal Demonstration Partnership, The National Academies. Faculty Representative for the University of Arkansas for Medical Sciences, Appointed May 2004-2007

University of Arkansas for Medical Sciences ARIA Development Committee, Member 2001-2009

University of Arkansas for Medical Sciences Human Research Advisory Committee (IRB).
Member (all committees) 1993- 2003;
Chairman (Committees 1&3), 2001- 2003.
Chair-Designee 2008-present

COMMITTEES & APPOINTMENTS: (Continued)

UNIVERSITY

University of Arkansas for Medical Sciences Academic Senate Council. October 1993-1997.

College (selected)

University of Arkansas for Medical Sciences College of Pharmacy, Faculty Parliamentarian, 2008-10

University of Arkansas for Medical Sciences College of Pharmacy, Assessment Committee, Member, 2005-2007.

University of Arkansas for Medical Sciences College of Pharmacy, Task Force on Student Wellness Member, 2004-2005.

University of Arkansas for Medical Sciences College of Pharmacy, Executive Committee, Member 2003-present.

University of Arkansas for Medical Sciences College of Pharmacy, Non-Traditional Pharm.D. Program Admissions Committee. Member, 2003-2004.

University of Arkansas for Medical Sciences College of Pharmacy, Promotion and Tenure Committee. Member, 1998-2003; Chairman, 2000-2003.

University of Arkansas for Medical Sciences College of Pharmacy, Pharmacy Student Research Committee, member, 2001-2003.

Faculty Advisor, Phi Delta Chi Professional Fraternity, Beta Eta Chapter, University of Arkansas for Medical Sciences College of Pharmacy. January 1993-June 2002.

RESEARCH EXPERIENCE:

Grants

“Bioterrorism Training and Curriculum Development Program” Faculty member (16% salary relief), Funding Source: The Health Resources and Service Administration (HRSA), US Department of Human Services, PI: Howell Foster, Pharm.D. 9/1/03- 9/1/05 (Status: *Completed*)

“UARK 2002-39 Open-Label Pharmacokinetic Study of Oral Voriconazole: Pre and Post Autologous Peripheral Stem Cell Transplantation” Principle Investigator, Funding Source: Pfizer Inc. Funding: 12/20/02- (Status: *Data analysis and manuscript preparation*)

“Comparison of the pharmacokinetics of AmBisome administered either as a single 15mg/kg dose, weekly as a single dose (7.5mg/kg), or daily as a single dose (1mg/kg).” Principle Investigator, Funding Source: Fujisawa Inc. Funding: 10/01/2001 -(Status: *Completed, see publications*)

“Determining the influence of intestinal CYP3A4 and P-glycoprotein on the oral bioavailability of itraconazole capsules.” Principle Investigator, Funding source: Society of Infectious Diseases Pharmacists. Funding: 10/2000-10/2002 (Status: *Data analysis and manuscript preparation*)

RESEARCH EXPERIENCE: *Grants (Continued)*

“Cross-sensitivity of patients with reported penicillin allergy/hypersensitivity to either imipenem or cefepime.” Principle Investigator, Funding source: Unrestricted Educational Grant Merck and Co. Funding: 01/2000 – 01/2001 (Status: *Closed*)

“The effect of IL-6 on hepatic cytochrome P4503A metabolism of itraconazole in primary rat hepatocytes.” Principle Investigator/Mentor, Funding source: American Association of Colleges of Pharmacy Merck Scholar Program Award. Funding: 07/1999 – 07/2000 (Status: *Completed*).

“Incidence of imipenem hypersensitivity reactions in febrile neutropenic cancer patients with self-reported penicillin allergy.” Principal Investigator, Funding source: Unrestricted Educational Grant Merck and Co. Funding: 7/1998-7/1/1999 (Status: *Completed, see publications*).

“The effect of grapefruit juice on the systemic availability of itraconazole and its metabolite.” Principal Investigator Funding: American College of Clinical Pharmacy Research Institute Pharmacotherapy Research Award. Funding: 7/1998-7/1999 (Status: *Completed, see publications*).

“The effect of grapefruit juice on the systemic availability of itraconazole capsules” Principal Investigator, Funded with discretionary accounts (Status: *Completed, see publications*).

“Steady state pharmacokinetics of itraconazole solution in autologous bone marrow transplant recipients” Principal Investigator, Funding source: The American Foundation for Pharmaceutical Education and The Burroughs Wellcome Fund. Funding: 12/1997-2/2000 (Status: *Completed*) (FDA IND 56,006).

“Effects of interleukin-6 on hepatic metabolism of the triazole antifungal itraconazole” Principal Investigator, Funding source: Society of Infectious Diseases Pharmacists, ACRC Partners in Research. Funding: [Student stipend support ACRC Partners in Research.summer 1997-8].10/1997-10/1998 (Status: *Completed, see publications*)

“Identification of Variables to Estimate the Risk of Amphotericin B (AmB)-Induced Nephrotoxicity in the Multiple Myeloma (MM) Bone Marrow Transplant (BMT) Population.” Principal Investigator, Funded with discretionary accounts (Status: *Completed, see publications*)

“Development of a Rapid and Sensitive HPLC Method for the Determination of Voriconazole Concentrations in Human Serum.” Principal Investigator, student stipend from ACRC Partners in Care Program (Status: *Completed, see publications*).

“Characterization of a previously uncharacterized diastereomers of itraconazole” Principle investigator/Mentor, Funding source: SILO Advisory Council Undergraduate Research Fellowship, Funding: 01/1996- 01/1997 (Status: *Completed*).

"A study of the steady-state pharmacokinetics of itraconazole and hydroxyitraconazole in pediatric patients." Principle Investigator, Funding source: UAMS Foundation Medical Endowment Fund; Funding: *Terminated, funding redirected to ITZ capsule /GFJ study.* (Status: *Completed*)

RESEARCH EXPERIENCE: *Grants (Continued)*

"A study to determine the pharmacokinetics of itraconazole and its hydroxy-metabolite in allogeneic bone marrow transplant patients." Principal Investigator, Funded with discretionary accounts and student stipend from ACRC Partners in Care Program (Status: *Completed*).

"A study to determine single-dose absorption and relative bioavailability of an extemporaneous oral suspension preparation of itraconazole" Principal Investigator, Funded with discretionary accounts (Status: *Completed, see publications*).

"An international interlaboratory trial for the validation of the determination of itraconazole and hydroxyitraconazole using HPLC." Janssen Research Institute, Belgium (Status: *Completed*).

"A prospective surveillance of Gram negative isolates from the intensive care units of a university hospital." Principal Investigator, Funding source: Merck & Co. Funding: 01/1995 (Status: *Completed*).

INVESTIGATOR IND:

IND 56,006. "Steady state pharmacokinetics of itraconazole solution in autologous bone marrow transplant recipients". 12/1997-11/2004

PRESENTATIONS:

LOCAL: (≤ 5 years)

June 2006 "Human Papilloma Virus" Invited Speaker, Arkansas Pharmacists Annual Meeting, Little Rock, AR. Sponsored by Merck & Co.

October 2006 "Evaluating the Antibiogram: A Necessity for Curtailing Resistance in Your Institution- Pharmacist Must Get Involved Evaluating the Antibiogram – Gram-positive Resistance" Invited Speaker, 40TH Annual Arkansas Association of Health-System Pharmacists Fall Seminar, Big Cedar, MO

May 2007 "Update on Community Acquired Methicillin Resistant *Staphylococcus aureus*." Invited Speaker, Annual Arkansas Association of Health-System Pharmacists Spring District Meeting, Little Rock, AR

August 2009 "Promotion and Tenure in the College of Pharmacy: Viewpoint of the Pharmacy Practice Department Chair" UAMS College of Pharmacy, Faculty Retreat, Little Rock, AR

REGIONAL:

April 1997 "Antibiotic Update 1996." Invited Guest Speaker to The Missouri Society of Hospital Pharmacists Annual Spring Meeting, April 11, St. Louis MO.

June 1997 "Treatment of Fungal Infections." Invited Guest Speaker to ServiShare Corp. Quarterly Meeting, June 18, Des Moines IA (Sponsored by The Liposome Co.).

PRESENTATIONS: *(Continued)*

REGIONAL:

- November 1997 "Advances in Antifungal Therapy" Invited Guest Speaker at "New Trends in the Management of Fungal Infections" Pharmacy C.E. Program Presented by The University of Illinois at Chicago College of Pharmacy. Rosemont, IL (Sponsored by The Liposome Co.).
- April 2004 "New and Existing Antifungal Agents" Invited Guest Speaker at South Dakota Society of Health System Pharmacists 2004 Annual Meeting. April 16th, 2004, Rapid City SD
- August 2004 "Drug Interactions of Antifungal Agents: Implications for the Transplant Patient" Invited speaker at the "Management strategies for invasive fungal infections in stem-cell transplant patients" regional meeting series. August 14th, 2004 Miami, FL; August 23rd 2004 Little Rock AR
- May 2005 "Novel Approaches to Polyene Dosing: Presenting Data from the 2004 Interscience Conference on Antimicrobial Agents and Chemotherapy" Invited Speaker, New Orleans area Health Systems Pharmacists, Sponsored by Fujisawa Healthcare Inc.

NATIONAL

(Invited Presentations)

- August 1995 "Challenging Cases in Infectious Diseases: Management of Fungal Infections." Panel Discussion Participant 1995 Annual Meeting of the American College of Clinical Pharmacy, Washington D.C.
- September 1997 "Therapeutic Choices in the Treatment of Invasive Fungal Infections." Guest panelist of The Liposome Company National Advisory Group for guidelines for the rationale use of lipid amphotericin B products. September 30, Toronto Canada (ICAAC) (Sponsored by Tufts Medical School and The Liposome Company)
- December 1997 "Rationale Use of the Lipid-Formulations of Amphotericin B" Invited Guest Speaker at the Sunrise Symposium Series, at the American Society of Health System Pharmacists Midyear Clinical Meeting, Atlanta GA. (Sponsored by The Liposome Company).
- March 1999 "Practical Tips on the Optimal Use of the Newer Azoles." Invited Speaker, March 19, at Focus on Fungal Infections 9. San Diego, CA.
- June 1999 "Early Presumptive Antifungal Therapy in Critically Ill Patients." Invited speaker at ASHP sponsored symposium Advances in Critical Care Pharmacotherapeutic Issues, June 7, at the 1999 Annual Meeting of the American Society of Health Systems Pharmacists, Reno, NV. (International Pharm Abstr. 1999;36:802. [Abstract # 3605139]).

PRESENTATIONS: *(Continued)*

NATIONAL

(Invited Presentations)

- October 1999 "Clinical Indications for the Lipid Formulations of Amphotericin B." Invited Speaker Guest Speaker at Satellite Symposium, Evolution of Antifungal Therapy, October 24, at the Annual Meeting of the American College of Clinical Pharmacy, Kansas City, MO.
- March 2001 "Drug-Drug and Drug-Food Interactions for the Antifungal Azoles: Practical considerations for the clinician." March 16, at Focus on Fungal Infections 11. Washington, D.C.
- October, 2002 "Antifungal Drug-Drug Interactions" Immunocompromised Hosts Society Panel Meeting, Invited Guest Speaker, Fujisawa Healthcare Inc. October 20, 2002, Albuquerque, NM.
- October, 2002 "Toxicities and Interactions of Current Antifungal Agents" Invited Guest Speaker for Advances in the Prevention and Management of Invasive Fungal Infections Satellite Symposium Preceding the 40th Annual Meeting of the Infectious Diseases Society of America (IDSA), sponsored by Fujisawa Healthcare Inc. October 24, 2002, Chicago, IL.
- October, 2002 "Update on Antifungal Therapies" Invited Guest Speaker for Mercy Resource Management Inc., Annual Meeting, October 29, 2002, St. Petersburg FL.
- March, 2003 "Novel Antifungal Agents: Pharmacological concerns in trial design." Faculty speaker at Focus on Fungal Infections 13, March 21, 2003 Maui, Hawaii
- October, 2004 "Maximizing the Pharmacokinetic Effects of Current Antifungal Therapies" Invited guest speaker for Management Strategies for Systemic Fungal Infections Satellite Symposium at the 42nd Annual Meeting of the Infectious Disease Society of America (IDSA), Sponsored by Fujisawa Healthcare Inc., October 1st, 2004, Boston MA
- October 2004 "IRB Issues Related to Special Populations" Invited Guest Speaker in the Curricular Track 4: Contemporary Issues with Clinical Trials, Challenges in Clinical Trial Design Symposium at the 2004 Annual Meeting of ACCP. October 27, 2004, Dallas TX
- March 2005 "Pharmacology & Pharmacokinetics of the Echinocandins: Focus on Micafungin" Invited guest speaker for the Canadian Pharmacist Organization Critical Care Group, Spring Meeting. March 15, 2005, Miami, FL
- March 2005 "Drug-Drug Interactions of Antifungal Agents and Implications for Patient Care" Faculty speaker at Focus on Fungal Infections 15. March 18, 2005, Miami FL
- October 2005 "Navigating the IRB" Invited panelist for "Meet the Experts Session" at the American College of Clinical Pharmacy Annual Meeting, October 25, 2005, San Francisco, CA

PRESENTATIONS: (Continued)

NATIONAL

(Invited Presentations)

- December, 2005 "The Role of New Antifungals: Focus on the Echinocandins" Faculty speaker at the Consorta meeting at the ASHP Midyear Clinical Meeting December 4, 2005, Las Vegas NV.
- January, 2006 "Practical Application of Pharmacodynamic Principles in the Intensive Care Unit: Focus on Antifungals" Invited faculty speaker at the Society of Critical Care Medicine Annual Meeting, January 9, 2006, San Francisco, CA
- April 2006 "Funding A Clinical Research Program-Grant Writing & Beyond:Identifying Funding Opportunities" Invited Faculty speaker at the ACCP Spring Practice and Research Forum, April 11 2006, Monterey, CA
- March 2007 "Mould Active Azoles: Pharmacokinetics, Drug Interactions in Neutropenic Hosts" Faculty speaker at Focus on Fungal Infections 17. March 9, 2007, San Diego, CA
- March 2009 "Antifungal Therapeutic Drug Monitoring: The Do's and The Don't's" Faculty speaker at Focus on Fungal Infections 19. March 6, 2009, Sanibel Island, FL
- December 2009 "Introduction to Academia: A Department Chair's Perspective" Invited Faculty Speaker at the ASHP Midyear 2009 Symposium: Preparing for Faculty Positions: Insights From the Ivory Tower. December 5, 2009, Las Vegas NV
- March 2010 Therapeutic Drug Monitoring: When and how?" Faculty speaker at Focus on Fungal Infections 20. March 5, 2010, New Orleans, LA

(Scientific Presentations- *Primary Author*)

- December 1989 "Establishing guidelines for minimum intravenous admixture volumes based on osmolality for commonly administered antimicrobial agents." Poster presented December 7, 1989, at the 24th ASHP Midyear Clinical Meeting; Atlanta GA. (International Pharm Abstr.1990;27:322. (Abstract # 2702008))
- February 1992 "A five-year retrospective surveillance of the treatment and microbiologic outcomes of fungal urine cultures positive for *Candida albicans*: A pilot." Poster presented February 11, 1992, at the 2nd Winter Practice and Research Forum of the American College of Clinical Pharmacy, Phoenix, AZ. (Pharmacotherapy 1991;11(6):P-34 (Abstract #23).
- February 1993 "Surveillance of the treatment and microbiologic outcome of candiduria in a university hospital." Poster presented February 9, 1993 at the 3rd Winter Practice and Research Forum of the American College of Clinical Pharmacy, Ft. Lauderdale, FL. (Pharmacotherapy 1992;12:502 (Abstract #47)).

PRESENTATIONS: *(Continued)*

NATIONAL

(Scientific Presentations – Primary Author)

- November 1994 "A prospective surveillance of antibiotic susceptibilities of Gram-negative isolates from the intensive care units of a university hospital." Slide presentation for the 12th Annual Merck Research Laboratories Health Science Associate Pharmacy Research Conference, Philadelphia, PA.
- February 1995 "A prospective surveillance of antibiotic susceptibilities of gram-negative isolates from the intensive care units of a university hospital." Poster presented February 14, 1995, at the 1995 Winter Practice and Research Forum of the American College of Clinical Pharmacy, Orlando, FL. (Pharmacotherapy 1995; 15:113 [Abstract 38]).
- September 1995 "A study to determine the pharmacokinetics of itraconazole and its metabolite, hydroxyitraconazole in allogeneic bone marrow transplant recipients." Poster presented September 18, at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco CA. ([Abstract #971] In: Programs and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 17-20 September 1995)
- October, 1996 "Rapid and sensitive HPLC determination of itraconazole (ITZ) and its hydroxy-metabolite in human serum." Poster presented October 30, at the American Association of Pharmaceutical Scientists, Seattle WA. ([abstract APQ 1142]. Pharm Res 1996;13 (suppl):S-38).
- September, 1998 "Effects of interleukin-6 on hepatic metabolism of the triazole antifungal itraconazole" Oral platform presentation, September 24, at the Society of Infectious Diseases Pharmacists Annual Meeting, San Diego, CA.
- September, 1998 "Identification of variables to estimate the risk of amphotericin B-induced nephrotoxicity in the multiple myeloma bone marrow transplant population" Platform presentation, September 26, at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. ([Abstract 142-J] In: Programs and Abstracts of the 38th Interscience Conference of Antimicrobial Agents and Chemotherapy, 24-27 September 1998).
- November, 1998 "A lesson in column efficiency: the effect of column particle size on the chromatographic determination of itraconazole and hydroxyitraconazole" Poster presented November 18, at the American Association of Pharmaceutical Scientists, San Francisco, CA. ([Abstract 3485]. Pharm Sci 1998;1:S-501).
- October, 1999 "Effect of grapefruit juice on the systemic availability of itraconazole oral solution" poster presentation of 1998 Research Award, October 25, at the 1999 ACCP Annual Meeting, Kansas City, MO.

PRESENTATIONS: (*Continued*)

NATIONAL

(Scientific Presentations- *Primary Author*)

November, 2000 "The effect of interleukin-6 on the hepatic metabolism of itraconazole and its metabolite hydroxyitraconazole." Platform presentation, November 7, at the Annual Meeting of the American College of Clinical Pharmacy, Los Angeles, CA. ([Abstract 208]. Pharmacotherapy 2000;20:1263).

November, 2004 "Comparison of liposomal amphotericin B plasma and tissue concentrations following a single large (15mg/kg) dose or daily 1mg/kg dosing." Poster presented Saturday November 1, at the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy, Washington, DC. ([Abstract A-33] In: Programs and Abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy, pg. 3 November, 2004).

INTERNATIONAL

(Scientific Presentations – *Primary Author*)

June 1993 "Surveillance of urinary tract fungal isolates from a university hospital. 1990-1992". Oral platform presentation June 30, 1993 at the 18th International Congress of Chemotherapy, Stockholm, Sweden. ([Abstract #1074] In: Abstracts of the 18th International Congress of Chemotherapy: 301.1993).

NATIONAL

(*Scientific Presentations- Contributing Author*)

December, 1991 Lewis RK et al. "Gram-negative sepsis disease audit: documenting the impact of monoclonal antibody therapy in the management of gram-negative sepsis." Poster presented at the 26th ASHP Midyear Clinical Meeting; New Orleans, LA. (International Pharm Abstr. 1992; 29:110 (Abstract # 2900459))

October, 1992 Occhipinti DJ, et al. "Incidence, treatment, and microbiologic outcome of non-albicans fungal urinary tract pathogens." (In: Programs and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy 11-14 October, 1992; Anaheim, CA (#839))

May, 1995 Olsen KE, et al. "Estimation of azithromycin concentrations in pulmonary tissues and serum after multiple oral doses in normal volunteers." (In Programs and Abstracts of the American Thoracic Society International Conference 21-24 May 1995; Seattle WA.)

October, 2001 McCabe BJ, et al. "How Important is the Grapefruit Juice/Drug Interaction Problem?: A Critical Look." (Platform) American Dietetic Association. St. Louis, MO. October 20-23, 2001. Food & Nutrition Conference and Exhibition, #276.

December, 2001 Penzak SR, et. al. "Rapid and Sensitive High Performance Liquid Chromatographic (HPLC) Method for the Determination of Ritonavir in Human Plasma." (In: Programs and Abstracts of the 41st Interscience Conference of Antimicrobial Agents and Chemotherapy, December, 2001; Chicago, IL. A-496.)

PRESENTATIONS: (Continued)

NATIONAL

(Scientific Presentations- *Contributing Author*)

- April, 2002 Karyekar CS, et. al. "Effect of itraconazole on P-glycoprotein-mediated transport of cimetidine in MDR1-MDCK cells." Poster presented at ACCP 2002 Spring Forum, Savannah, GA, April 9, 2002. ([Abstract 66E]. Pharmacotherapy 2002;22:414). Also presented at the ASN/ISN World Congress of Nephrology, San Francisco, CA, October 14, 2001.
- April, 2003 Karyekar CS, et al. "Itraconazole inhibits P-glycoprotein-mediated tubular secretion of cimetidine in humans." Poster presented at the 2003 ACCP Spring Practice and Research Forum, Palm Springs, CA ([Abstract 93]. Pharmacotherapy 2003;23:405).
- July, 2005 Neill KK, et al. "An experience in evidence-based policy application." Poster presented at the 2005 AACP Annual Meeting, Cincinnati, OH [Abstract]. Am J Pharm Ed 2005;69:447.
- October 2006 Bariola JR, et al. "Persistent antigenuria during therapy for blastomycosis." Poster presented at the 2006 IDSA Annual Meeting, Toronto, Ontario, Canada ([Abstract 564]).
- July 2008 Gervasio J, et al. "Survey of the perceived value of various postgraduate pharmacy teaching programs." Podium presentation at the 2008 AACP Annual Meeting, in Chicago, IL.
- April 2009 Amsden JR, et al. "Steady state pharmacokinetics of oral voriconazole and its primary metabolite (UK121-265) pre and post autologous peripheral stem cell transplantation" Poster presented at the 2009 ACCP/ESCP International Congress on Clinical Pharmacy, Orlando, FL [Abstract 102]
- July 2009 Bosso JA, et al. "National benchmarking of departments of pharmacy practice." Poster presentation presented at the 2009 AACP Annual Meeting in Boston, MA

INTERNATIONAL

(Scientific Presentations- *Contributing Author*)

- June 1993 Occhipinti DJ, et. al. Primary Urinary tract infection due to *Candida parapsilosis*: A report of four cases." Oral platform presentation June 30, 1993 at the 18th International Congress of Chemotherapy, Stockholm, Sweden. ([Abstract # 1075] In: Abstracts of the 18th International Congress of Chemotherapy: 302.1993).

PRESENTATIONS: *(Continued)*

NATIONAL

(Scientific Presentations- presented by mentored Students, Residents, Fellows)

December 1996 Christensen K, et al. "Bioavailability of an extemporaneous preparation of itraconazole" Poster presented December 11, at the 31st American Society of Health System Pharmacists Midyear Clinical Meeting, New Orleans, LA (International Pharm Abstr.1996;33:2300.[Abstract # 3313554]).

September 1997 Penzak SR, et al. "Epidemiological investigation of a Gram-negative bloodstream isolate outbreak among cancer patients." ([Abstract J-213] In: Programs and Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, 17 September 1997; Toronto, Canada).

September 1998 Penzak SR, et al. "Effect of grapefruit juice on the systemic availability of itraconazole capsules" Poster presented September 27, at the 38th Interscience Conference of Antimicrobial Agents and Chemotherapy, ([Abstract 197-A] In: Programs and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 24-27 September 1998; San Diego, CA).

September 1999 McConnell SA, et al. "Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with self-reported penicillin allergy." [Abstract 1088-M] (In: Programs and Abstracts of the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy, 26-29 September 1999, San Francisco, CA).

October 1999 McConnell SA, et. al. "Prevention of bloodstream infections with antimicrobial/antiseptic impregnated central venous catheters (ACVC): Where Are the Data?"([Abstract 449] Clin Infect Dis 1999;29:1041). October 1999, Philadelphia PA

July 2000 Franks AH, et. al. "The effect of interleukin-6 on hepatic metabolism of the triazole antifungal itraconazole in primary rat hepatocytes" Poster presentation of the Merck Research Scholar Award Program for Professional Degree Pharmacy Students, July 11, at the AACP Annual Meeting, San Diego, CA. [Abstract] (Am J Pharm Ed 2000; 64 (supp 1):122S).

September 2000 McConnell SA, et. al. "Sex-related differences in oral clearance observed for itraconazole when itraconazole oral solution is administered with water but not grapefruit juice" Poster presented September 18, at the 40th Interscience Conference of Antimicrobial Agents and Chemotherapy, [Abstract 862] (In: Programs and Abstracts of the 40th Interscience Conference of Antimicrobial Agents and Chemotherapy, pg. 28, 17-20 September 2000, Toronto, Canada).

November 2004 Amsden JR, "Characterizing the intestinal metabolism on the pharmacokinetics (pk) of oral itraconazole (itz) capsules." Poster presented Saturday November 1, at the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy, Washington, DC. [Abstract A-35] In: Programs and Abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy, pg 3 November, 2004; Washington, DC.

PRESENTATIONS: (*Continued*)

NATIONAL

(Scientific Presentations- *Presented by mentored Students, Residents, Fellows*)

REGIONAL (*Selected Presentations*)

April 1997 Polston S, et al. "A Pilot study to identify variables to estimate the risk of amphotericin B-induced nephrotoxicity in the multiple myeloma bone marrow transplant population". Presented at the Midwest Pharmacy Residents Conference, Memphis, TN April 17th 1997.

April 1999 Warmack TS, et al. "Incidence of Imipenem Hypersensitivity Reactions in Febrile Neutropenic Cancer Patients with Self-Reported Penicillin Allergy." Presented at the Midwest Pharmacy Residents Conference. St. Louis, Missouri, April 16, 1999.

LOCAL (*Selected Presentations*)

April 1998 Watterson KS, et al. "A lesson in column efficiency, the effect of column particle size on the chromatographic determination of itraconazole and hydroxyitraconazole." presented at the 5th Arkansas Undergraduate Research Conference, Arkadelphia AR) In: Proceedings of the 5th Arkansas Undergraduate Research Conference, April 17-18, 1998 Arkadelphia AR.

July 1998 Hartman A, et al. "The effect of interleukin-6 on the hepatic metabolism of the triazole antifungal itraconazole." Presented at the Arkansas Cancer Research Center Partners in Research Student Scientific Symposium, July 28, 1998.

PUBLICATIONS:

(*Refereed Original Research and Scholarly Review Articles*)

1. **Gubbins PO**, Bertch KE. Drug absorption in gastrointestinal disease and surgery. Pharmacotherapy 1989;9(5):285-95.
2. **Gubbins PO**, Bertch KE. Drug absorption in gastrointestinal disease and surgery: Clinical pharmacokinetic and therapeutic implications Clin Pharmacokinet. 1991;21(6):431-47.
3. **Gubbins PO**, Piscitelli SC, Danziger LH. *Candida albicans* urinary tract infections: A comprehensive review. Pharmacotherapy 1993;13:110-27.
4. **Gubbins PO**, Piscitelli SC, Danziger LH. Urinary tract infections caused by *Candida* species. J Pract Nursing 1993;43:25-34. (Reprinted as C.E. article in Pharmacy Times 1993;(59):120-129).
5. **Gubbins PO**, Occhipinti DJ, Danziger LH. Surveillance of treated and untreated funguria in a university hospital" Pharmacotherapy 1994;14:463-70.
6. Occhipinti DJ, **Gubbins PO**, Schreckenberger P, Danziger LH. Frequency, pathogenicity and microbiologic outcome of non-*Candida albicans* candiduria. Eur J Clin Micro Infect Dis. 1994;13:459-67.

PUBLICATIONS: (Continued)

(Refereed Original Research and Scholarly Review Articles)

7. Schutze GE, Hickerson SL, Fortin EM, Schellhase DE, Darville T, **Gubbins PO**, Jacobs RF. Blastomycosis in pediatric patients. Clin Infect Dis 1996; 22:496-502.
8. Christensen K, **Gubbins PO**. Treatment of vancomycin-resistant staphylococcal infections. Ann Pharmacotherapy 1996; 30:288-90.
9. Olsen KM, San Pedro GS, Gann LP, **Gubbins PO**, Halinski DM, Campbell GD. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996;40:2582-85.
10. Rapp RP, **Gubbins PO**, Evans M. Lipid complex amphotericin B: A review. Ann Pharmacother 1997;31:1174-86.
11. Christensen K, **Gubbins PO**, Gurley BJ, Bowman JL, Buice RG. A study to determine single-dose absorption and relative bioavailability of an extemporaneous oral suspension preparation of itraconazole. Amer J Health Syst Pharm 1998;55:261-65.
12. Penzak SR, **Gubbins PO**. Preventing and treating azole-resistant oropharyngeal candidiasis in HIV-infected patients.. Amer J Health System Pharm. 1998;55:279-82.
13. Peachy PR, **Gubbins PO**, Martin RE. The association between cryptococcal variety and immunocompetent and immunocompromised hosts. Pharmacotherapy 1998;18:255-64.
14. **Gubbins PO**, Gurley BJ, Bowman JL. A rapid and sensitive liquid chromatographic method for the determination of hydroxy-itraconazole (OH-ITZ) and itraconazole (ITZ) in human serum. J Pharmaceut Biomed Anal 1998;16:1005-12.
15. **Gubbins PO**, Bowman JL, Penzak SR. Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplant recipients. Pharmacotherapy 1998;18:549-64.
16. Penzak SR, **Gubbins PO**, Rodvold KA, Hickerson SL. Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monitor 1998;20:261-65.
17. Penzak SR, **Gubbins PO**, Gurley BJ, Wang PL, Saccente M. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monitor 1999; 21:304-9.
18. **Gubbins PO**, McConnell SA, Penzak SR. Management of funguria. Amer J Health-Sys Pharm 1999;56:1929-35.
19. Penzak SR, **Gubbins PO**, Stratton S, Anaissie EJ. Epidemiological investigation of a Gram-negative bloodstream isolate outbreak among cancer patients. Infection Control Hosp Epidemiol 2000; 21:597-599.
20. McConnell SA, Warmack TS, Penzak SR, Anaissie EJ, **Gubbins PO**. Incidence of imipenem hypersensitivity reactions in febrile neutropenic BMT patients with self-reported penicillin allergy. Clin Infect Dis 2000;31:1512-14.

PUBLICATIONS: *(Continued)*

(Refereed Original Research and Scholarly Review Articles)

21. Penzak SR, Lawhorn WD, **Gubbins PO**. Rapid and sensitive high performance liquid chromatographic method for the determination of ritonavir in human plasma. Int J Clin Pharmacol Ther 2001; 39:400-5.
22. **Gubbins PO**, Penzak SR, Polston S, McConnell SA, Anaissie E. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002; 22:961-71.
23. **Gubbins PO**, Melchert RB, McConnell SA, Franks AM, Penzak SR, Gurley BJ. The effect of interleukin-6 on the hepatic metabolism of itraconazole and its metabolite hydroxyitraconazole using primary human hepatocytes. Pharmacol 2003; 67:195-201.
24. Karyekar CS, Eddington ND, Garimella TS, **Gubbins PO**, Dowling TC. Evaluation of renal p-glycoprotein-mediated drug Interactions in mdr1-mdck cells. Pharmacotherapy 2003; 23:436-42.
25. McConnell SA, **Gubbins PO**, Anaissie EJ. Do Antimicrobial-Impregnated Central Venous Catheters Prevent Catheter-Related Bloodstream Infections? Clin Infect Dis 2003; 37: 65-72.
26. Kennedy RH, **Gubbins PO**, Luer M, Reddy IK, Light KE. Developing and sustaining a culture of scholarship. Am J Pharm Ed 2003; 67:1-18.
27. **Gubbins PO**, McConnell SA, Gurley BJ, Fincher TK, Franks AM, Williams DK, Penzak SR, Saccante M. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers. Pharmacotherapy 2004; 24:460-7.
28. Karyekar CS, Eddington ND, Briglia A, **Gubbins PO**, Dowling TC. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol 2004; 44:919-27.
29. McConnell SA, **Gubbins PO**, Anaissie EJ. Are antimicrobial-impregnated catheters effective? Replace the water and grab your washcloth, because we have a baby to clean. Clin Infect Dis 2004; 39:1829-33.
30. Amsden JR, Warmack TS, **Gubbins PO**. Tick borne bacterial, rickettsial, spirochetal, and protozoal infectious diseases in the United States: A comprehensive review. Pharmacotherapy 2005; 25:191-210.
31. **Gubbins PO**, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opinion on Pharmacotherapy 2005; 6:2231-43.
32. **Gubbins PO**, Krishna G, Sansone-Parsons A, Penzak SR, Dong L, Matinho M, Anaissie EJ. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006; 50:1993-99.
33. **Gubbins PO**. Drug-drug interactions of antifungal agents and implications for patient care. J Invasive Fungal Infect 2007;1:144-55.

PUBLICATIONS: *(Continued)*

(Refereed Original Research and Scholarly Review Articles)

34. **Gubbins PO.** Mould Active Azoles: Pharmacokinetics, drug interactions in neutropenic hosts. Curr Opin Infect Dis 2007;20:579-86.
35. **Gubbins PO,** Gurley BJ, Williams DK, Penzak SR, McConnell SA, Franks AM, Saccente M. Examining sex-related differences in enteric itraconazole metabolism with grapefruit juice. Eur J Clin Pharmacol 2008;64:293-301.
36. **Gubbins PO.** Drug–drug Interactions of antifungal agents of importance in dermatology. Current Medical Literature – Dermatology 2008;13:1-13.
37. **Gubbins PO,** Amsden JR, McConnell SA Anaissie EJ. The pharmacokinetics and buccal mucosal concentrations of a 15 mg/kg total dose of liposomal amphotericin B either as a single (15mg/kg) dose, weekly dose (7.5mg/kg), or a daily dose (1mg/kg) in hematopoietic stem cell transplant patients. Antimicrob Agents Chemother 2009;53:3664-74.
38. MacPherson DW, Gushulak BD, Baine WB, Bala S, **Gubbins PO,** Holtom P, Segarra-Newnham M. Population mobility, globalization, and antimicrobial drug resistance. Emerging Infect Dis 2009;15:1727-32.
39. **Gubbins PO,** Heldenbrand SD. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010;53:95-113.
40. Ratka A, **Gubbins PO,** Motycka CA, Gervasio JM, Johnson MS, Maddox RW. Self-assessed Proficiency, Confidence, and Application of Various Skills Learned During the Postgraduate Pharmacy Teaching Skills Development Programs. Curr Pharm Teaching and Learning 2010;(accepted).
41. Bariola JR, Durkin M, Bensadoun E, Wheat J, **Gubbins PO,** Bradsher RW. “Clinical utility of an assay for *Blastomyces dermatitidis* antigen in newly diagnosed, currently treated and previously treated blastomycosis. Clin Vaccine Immuno 2010; (accepted).
42. Bosso JA, Chisholm-Burns M, Nappi J, **Gubbins PO,** Ross LA. Should Academic Pharmacy Departments Engage in Benchmarking? Am J Pham Ed 2010; (submitted 2010)
43. Meyer SC, **Gubbins PO,** Anaissie EJ. “False Positive Test for Aspergillus galactomannan antigenemia related to herbal supplement use in a cancer patient. Pharmacotherapy 2009; (*In preparation*)

Letters/Viewpoints

1. **Gubbins PO,** Bradsher RW. Questionable susceptibility reporting in a multi-centered trial. Antimicrob Agent Chemother 1995;39:1012-1013.
2. Penzak SR, **Gubbins PO.** Accuracy and factual information needed: Clarifications on antimicrobial resistance primer. Amer J Health System Pharm 1997; 54: 2744-48.

PUBLICATIONS: (Continued)
(Letters/Viewpoints)

3. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, et al. Clinical Research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis 2006;43:1031-9.

Web-based Teaching Cases

1. **Gubbins PO**, Catanzaro A, Berkovich B, Harrity S, Cummins D, Hoffman H. "Rosa Lopez: A 16 year old Hispanic female with a reactive tuberculin skin test (TST) has recently given birth" The Office of Educational Computing for the National Tuberculosis Curriculum Consortium (Contract N01-HR-36157) Jan. 2010.

Book Chapters

1. **Gubbins PO**. Review of Antimicrobial Agents. In: Hynniman, Ed. Nursing In-service Program; 1st and 2nd, 3rd editions. Pharmacy Systems Inc, Dublin OH.; 1990 and 1991; 1993; Chapter 6.
2. **Gubbins PO**, McConnell SA, Penzak SR. Drug Interactions Associated with Antifungal Agents. Chapter 8, pgs. 185-217. In: Piscitelli SC, Rodvold KA, Ed. Drug Interactions in Infectious Diseases Humana Press, Totowa, NJ, 2001.
3. **Gubbins PO**. Fungal Infections: The Role of Prophylactic and Empiric Antifungal Therapy in ICU Patients. U.S. Perspective In: Weinstein RA, Bonten M, Ed. Perspectives on Critical Care Infectious Diseases: Infection Control in the ICU Environment, Chapter 8, pgs.93-105. Kluwer Academic Publishers, Boston MA, November, 2001.
4. **Gubbins PO**. Management of Fungal Infections. In Pharmacotherapy Self-Assessment Program 4th Ed. Book 4, Infectious Diseases I & II. 2001; 285-320.
5. Amsden JR, Warmack TS, **Gubbins PO**. Zoonoses. In Pharmacotherapy Self-Assessment Program 5th Ed. Book 6, Infectious Diseases I & II 2004; 1-42.
6. **Gubbins PO**. Fungal Infections. In Fink MP, Abraham E, Vincent JL, Kochanek P, Eds. Textbook of Critical Care Section VIII, Chapter 157, pgs. 1345-1357 5th ed. Saunders, div Elsevier Publishers, Philadelphia PA. 2005
7. **Gubbins PO**, McConnell SA, Amsden JR. Drug Interactions Associated with Antifungal Agents. Chapter 10, pgs.289-337. In: Piscitelli SC, Rodvold KA, Ed. Drug Interactions in Infectious Diseases 2nd ed, Humana Press, Totowa, NJ. 2005
8. **Gubbins PO**. The systemically acting azoles. In: Wingard J and Anaissie E, eds. Fungal infections in the immunocompromised patient, Chap. 17, pgs 457-84. Taylor & Francis Group Boca Raton, FL. 2005.
9. **Gubbins PO**. Drug-drug interactions of antifungal agents and implications for patient care. In: Perfect J, Ed. Antifungal Strategies and Complications in High Risk Patients Chap 4.3. pgs 238-72, Remedica, London, UK 2009.

PUBLICATIONS: (*Continued*)
(*Bookchapters*)

10. **Gubbins PO**, Anaissie EJ. Antifungal Therapy: Development of Antifungal Drugs In: Anaissie EJ, McGinnis MR, Pfaller MA, eds Clinical Mycology 2nd ed, Chapter 7, pgs 167-199 Churchill-Livingstone, New York, NY. 2009.
11. **Gubbins PO**. Fungal Infections. In Fink MP, Abraham E, Vincent JL, Kochanek P, Eds. Textbook of Critical Care Section VI, Chapter 157, pgs. 6th ed. Saunders, div Elsevier Publishers, Philadelphia PA. 2010 (*In Press*)
12. **Gubbins PO**, Amsden JR. Drug Interactions Associated with Antifungal Agents. Chapter 10, In: Piscitelli SC, Rodvold KA, Pai M. Ed. Drug Interactions in Infectious Diseases 3rd ed, Springer, NY, NY. 2010

Bibliographies

1. Occhipinti DJ, **Gubbins PO**, Danziger LH. Fungal Infections. *Hosp Pharm.* 1994;29:606

Monographs

1. **Gubbins PO**. Lipid Amphotericin B Formulations. In: University Hospital Consortium Monograph Series. October 1996;4:1-22.
2. **Gubbins PO**. Liposomal and Lipid Amphotericin B Formulations Update. In: University Hospital Consortium Drug Monograph. 2001;9:1-54.

Invited Non peer-review references

1. **Gubbins PO**. Antibiotic efficacy review 1996. *Pharmacy Practice News*; September 1996; pg13-16.
2. **Gubbins PO**. Defining the role of lipid-based amphotericin B formulations. *Society of Infectious Diseases Pharmacists Newsletter*. 1998;8(2):6.
3. **Gubbins PO**, Anaissie EJ. Overview of Antifungal Agents. *Pharmacy Practice News*; October 2002; pgs 25-30. Reprinted in *Infectious Diseases Special Edition* October 2002; 5:65-70, and as a pocket card.
4. **Gubbins PO**, Anaissie EJ. Overview of Antifungal Agents. *Pharmacy Practice News*; October 2003; pgs 29-34. Reprinted in *Infectious Diseases Special Edition* September 2003; 6:89-94.
5. **Gubbins PO**, Anaissie EJ. Overview of Antifungal Agents 2004. *Pharmacy Practice News Special Edition*; 2004;25-30. Reprinted in *Infectious Diseases Special Edition* October 2004 ; 7:53-58. and as a pocket card.
6. **Gubbins PO**, Anaissie EJ. Overview of Antifungal Agents 2005. *Pharmacy Practice News Special Edition*; 2005;45-50. Reprinted in *Infectious Diseases Special Edition* 2005;8:79-84 and as a pocket card.

PUBLICATIONS: (Continued)

(Invited Non peer-review references)

7. **Gubbins PO**, Anaissie EJ. Overview of Antifungal Agents 2006. Pharmacy Practice News Special Edition; 2006;59-64. Reprinted in Infectious Diseases Special Edition 2006;9;7-12, and as a pocket card.
8. **Gubbins PO**, Anaissie EJ. Overview of Antifungal Agents 2007. Infectious Diseases Special Edition 2007;10:52-66.
9. **Gubbins PO**, Anaissie EJ. Overview of Antifungal Agents 2009. Infectious Diseases Special Edition 2009;12:47-58.

PROFESSIONAL SERVICE:

The American Society of Health Systems Pharmacist (ASHP)

- 1992 ASHP Commission on Therapeutics. *ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery*. *Clin Pharm*. 1992; 11:483-513. (Contributor)
- 1996-99 Reviewer ASHP Therapeutic Position Statements on:
- Strategies to Prevent or Treat Multi-Drug Resistant Tuberculosis (1996)
 - Treatment of *Clostridium difficile* diarrhea (1997)
 - Non-Surgical Antimicrobial Prophylaxis (1999)
 - FDA Draft Guidance for Industry; Developing Antimicrobial Drugs—General Considerations for Clinical Trials (1998).

American College of Clinical Pharmacy (ACCP)

- 2008-09 Member, ACCP Awards Committee
- 2009-10 Member, ACCP Annual Meeting 2011 Planning Committee

Arkansas Department of Health and Human Services, Division of Health

- 2006- Member, Director's Advisory Committee for Antiviral Drug Use

Editorial Boards

- 2007-10 Member, International Advisory Board of *Current Medical Research and Opinion*
- 2009-11 Member, Editorial Board of *Antimicrobial Agents and Chemotherapy*

Mid-South College of Clinical Pharmacy (MSCCP)

- 2001 President-Elect, Mid-South College of Clinical Pharmacy
- 2002 President, Mid-South College of Clinical Pharmacy

The National Tuberculosis Consortium

- 2008-10 Participating Consortium Member, Case Author

The Society of Infectious Diseases Pharmacists (SIDP)

- 1993-94 Member, Ad Hoc Committee for Clinical Practice.
- 1998-99 Chairman, Working Group to Develop Post-Graduate Training Directory
- 1999-02 Member, Internet Committee, Member
- 2002-05 Research Awards Committee, Vice Chair 2003; Chair 2004-2005
- 2007 Member, Research Awards Committee
- 2008 Member, Interorganizational Relations

PROFESSIONAL SERVICE: (Continued)

(The Society of Infectious Diseases Pharmacists (SIDP))

2009-10 President-elect
2010-11 President

Phi Delta Chi Professional Fraternity

1995-96 Regional Collegiate Director Southcentral Region, Phi Delta Chi
1996-00 Regional Director of Alumni Affairs, Southcentral Region, Phi Delta Chi

United States Pharmacopeia

2006-10 Member, 2006-2010 Infectious Diseases Expert Committee

MEDIA APPEARANCES:

1997 Vancomycin Resistance among *Staphylococcus aureus*. Quoted *Arkansas Democrat Gazette* on the potential seriousness of vancomycin resistance among *Staphylococcus aureus*

2005 Treatment of the common cold. *Medical segment on KATV-7 Midday Arkansas*, January 11, 2005

Echinocandins offer antifungal therapy with low toxicity, few drug-drug interactions. *Internal Medicine News*. May 15, 2005; Quoted extensively in article; reproduced for *Entrepreneur.com* (<http://entrepreneur.com/tradejournals/article/print/132909041.html>)

Pharmacists benefit from employer competition. Quoted in *Arkansas Business Weekly*, October 10, 2005.

2006 HPV Vaccines. *Medical Segment on KARN News Radio 102.9* September 14-15, 2006

PEER REVIEWER: (Current)

Annals of Pharmacotherapy
Antimicrobial Agents & Chemotherapy
Current Research and Medical Opinion
Pharmacotherapy

CONSULTING/ EXPERT WITNESS:

Technical Advisor to Faulding Inc. - Technical Advisor Concerning issues related to the HPLC analysis of, and clinical trials involving investigational triazole antifungals. 1998-2000

United States of America v. David Jones – expert witness 1999-2000 Peronni & James Law Firm. January 2003-July 2003 Rieves, Rubens, & Mayton Lawyers, Appeared before Judge George Howard and provided testimony as to the transmissibility of Hepatitis B.

Michelle Rust v Carle Clinic – expert witness 2004-present Manion, Devens, McFetridge, Spiros & Schum, Ltd. Opinion on whether allergic reaction to amoxicillin in child caused a debilitating seizure

CONSULTING/ EXPERT WITNESS: *(Continued)*

Cardiokine Inc. – Scientific Consultant– Advisor concerning pharmacokinetic study design issues on a proposed clinical trial for investigational agent. 2005-

AWARDS:

1994 University of Arkansas for Medical Sciences, Medical Research Endowment Award
1996 Mentor, SILO Advisory Council Undergraduate Research Fellowship Program
1996 University of Illinois at Chicago College of Pharmacy Alumni Association Rising Star Award.
1997 Society of Infectious Disease Pharmacists Pfizer Research Award.
1997 American Association of Colleges of Pharmacy New Investigator Award.
1998 American College of Clinical Pharmacy Pharmacotherapy Research Award.
1999-00 Mentor American Associations of Colleges of Pharmacy Merck Research Scholar Program for Professional Degree Pharmacy Students.
2000 Society of Infectious Disease Pharmacists Pfizer Research Award
2003 Fellow, American College of Clinical Pharmacy
2006 Participant, University of Arkansas for Medical Sciences Leadership Institute
2007 Participant, American Association of Colleges of Pharmacy Academic Leadership Fellowship Program

MEMBERSHIP: *(Current)*

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmaceutical Association
American Society of Health Systems Pharmacists
American Society of Microbiology
Arkansas Pharmacist Association/Arkansas Association of Health-Systems Pharmacists
Honorary Member Rho Chi, Beta Iota Chapter, University of Arkansas for Medical Sciences
Society of Infectious Disease Pharmacists
University of Illinois at Chicago College of Pharmacy Alumni Association

REFERENCES: Available on request.